EA009989B1 - Лекарственное средство и его применение для лечения воспалительных и/или обструктивных заболеваний дыхательных путей - Google Patents

Лекарственное средство и его применение для лечения воспалительных и/или обструктивных заболеваний дыхательных путей Download PDF

Info

Publication number
EA009989B1
EA009989B1 EA200300929A EA200300929A EA009989B1 EA 009989 B1 EA009989 B1 EA 009989B1 EA 200300929 A EA200300929 A EA 200300929A EA 200300929 A EA200300929 A EA 200300929A EA 009989 B1 EA009989 B1 EA 009989B1
Authority
EA
Eurasian Patent Office
Prior art keywords
component
mcg
inhalation
drug according
propellant
Prior art date
Application number
EA200300929A
Other languages
English (en)
Russian (ru)
Other versions
EA200300929A1 (ru
Inventor
Кристофер Джон Монтагью Мид
Мишель Пере
Михаэль Пауль Пипер
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Publication of EA200300929A1 publication Critical patent/EA200300929A1/ru
Publication of EA009989B1 publication Critical patent/EA009989B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200300929A 2001-03-07 2002-02-26 Лекарственное средство и его применение для лечения воспалительных и/или обструктивных заболеваний дыхательных путей EA009989B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10110772A DE10110772A1 (de) 2001-03-07 2001-03-07 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
PCT/EP2002/001988 WO2002069945A2 (de) 2001-03-07 2002-02-26 Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren

Publications (2)

Publication Number Publication Date
EA200300929A1 EA200300929A1 (ru) 2004-04-29
EA009989B1 true EA009989B1 (ru) 2008-04-28

Family

ID=7676493

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300929A EA009989B1 (ru) 2001-03-07 2002-02-26 Лекарственное средство и его применение для лечения воспалительных и/или обструктивных заболеваний дыхательных путей

Country Status (18)

Country Link
EP (1) EP1372649B1 (enExample)
JP (1) JP2004521134A (enExample)
KR (1) KR20030081501A (enExample)
CN (1) CN1649588A (enExample)
AR (1) AR034213A1 (enExample)
AU (1) AU2002257587B2 (enExample)
BR (1) BR0207883A (enExample)
CA (1) CA2439763C (enExample)
CZ (1) CZ20032635A3 (enExample)
DE (1) DE10110772A1 (enExample)
EA (1) EA009989B1 (enExample)
HU (1) HUP0400782A3 (enExample)
IL (2) IL157326A0 (enExample)
MX (1) MXPA03008045A (enExample)
NZ (1) NZ528621A (enExample)
PL (1) PL363078A1 (enExample)
TW (1) TWI332833B (enExample)
WO (1) WO2002069945A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
WO2002096423A2 (en) * 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
WO2004084894A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases
PT1610787E (pt) * 2003-03-28 2008-04-23 Nycomed Gmbh Associação sinérgica compreendendo roflumilast e um agente anticolinérgico seleccionado de sais de tiotrópio para o tratamento de doenças respiratórias
EP1610788A1 (en) * 2003-03-28 2006-01-04 ALTANA Pharma AG Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
CA2533786A1 (en) * 2003-07-28 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
EP1504756A1 (en) * 2003-08-06 2005-02-09 Kyowa Hakko Kogyo Co., Ltd Medicament compositions comprising a heterocyclic compound and an anticholinergic
JP2007517820A (ja) * 2004-01-09 2007-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スコピンエステル及びニコチンアミド誘導体を基にした新規な医薬組成物
ES2413011T3 (es) 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
CA2550848C (en) * 2004-02-06 2013-02-26 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
AU2005210086A1 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
JP2007524699A (ja) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト ロフルミラストとグリコピロニウムとの組合せ物
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
SI1863476T1 (sl) 2005-03-16 2016-05-31 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
PL1971369T3 (pl) 2005-12-21 2010-01-29 Meda Pharma Gmbh & Co Kg Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych
NZ574533A (en) 2006-08-01 2011-05-27 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CA2749403A1 (en) 2009-01-13 2010-09-02 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
WO2012025473A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
WO2012025474A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Indazole compounds
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102670607A (zh) * 2012-05-28 2012-09-19 海南卫康制药(潜山)有限公司 复方盐酸氨溴索组合物及其制备方法
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
KR20160016966A (ko) * 2013-05-31 2016-02-15 인씨피오 디바이시스 에스에이 비구 리머 조립체

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040829A2 (en) * 1998-12-30 2000-10-04 Pfizer Inc. Prokinetic agents for treating gastric hypomotility and related disorders
WO2001046151A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
WO2001057025A1 (en) * 2000-01-31 2001-08-09 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
WO2001070746A1 (en) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
WO2001078741A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and budesonide
WO2002009689A1 (en) * 2000-07-27 2002-02-07 Smithkline Beecham Corporation Method for reducing exacerbations associated with copd
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040829A2 (en) * 1998-12-30 2000-10-04 Pfizer Inc. Prokinetic agents for treating gastric hypomotility and related disorders
WO2001046151A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
WO2001057025A1 (en) * 2000-01-31 2001-08-09 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
WO2001070746A1 (en) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
WO2001078741A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and budesonide
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
WO2002009689A1 (en) * 2000-07-27 2002-02-07 Smithkline Beecham Corporation Method for reducing exacerbations associated with copd

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARNES P.J.: "NONANTIMICROBIAL ASPECTS OF THERAPY", SEMINARS IN RESPIRATORY INFECTIONS, GRUNE AND STRATTON, ORLANDO, US, Bd. 15, Nr. 1, 2000, Seiten 52-58, XP000911165, ISSN: 0882-0546, Seite 53, Spalte 1, Absatz 2-Seite 56, Spalte 1, Zeile 20-40 *
DATABASE WPI, Derwent Publications Ltd., London, GB; AN 2001-626119, XP002212897, MATSUMOTO TATSUMI, TARUI NAOKI ET AL.: "New and known furoisoquinoline compounds as phosphodiesterase IV inhibitors" & WO 0170746 A (TAKEDA CHEMICAL INDUSTRIES LTD.), 27 September, 2001 (2001-09-27), Zusammenfassung *
DISSE B. ET AL.: "BA 679 BR, A NOVEL LONG-ACTING ANTICHOLINERGIC BRONCHODILATOR", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, Bd. 5/6, Nr. 52, 1993, Seiten 537-544, XP008002589, ISSN: 0024-3205, das ganze Dokument *
TAVAKKOLI A., REES P.J.: "Drug treatment of Asthma in the 1990s: achievements and new strategies", DRUGS, Bd. 57, Nr. 1, 1999, Seiten 1-8, XP001098314, ISSN: 0012-6667, Seite 3, Spalte 2, Absatz 2, Seite 4, Spalte 2, Absatz 2 *

Also Published As

Publication number Publication date
TWI332833B (en) 2010-11-11
EA200300929A1 (ru) 2004-04-29
EP1372649B1 (de) 2012-07-25
DE10110772A1 (de) 2002-09-12
CA2439763C (en) 2012-10-16
IL157326A0 (en) 2004-02-19
KR20030081501A (ko) 2003-10-17
WO2002069945A3 (de) 2003-01-30
HUP0400782A3 (en) 2012-09-28
IL157326A (en) 2011-12-29
CN1649588A (zh) 2005-08-03
BR0207883A (pt) 2004-07-27
AU2002257587B2 (en) 2007-05-10
AR034213A1 (es) 2004-02-04
MXPA03008045A (es) 2003-12-04
EP1372649A2 (de) 2004-01-02
CZ20032635A3 (cs) 2004-09-15
NZ528621A (en) 2005-04-29
CA2439763A1 (en) 2002-09-12
PL363078A1 (en) 2004-11-15
JP2004521134A (ja) 2004-07-15
WO2002069945A2 (de) 2002-09-12
HUP0400782A2 (hu) 2004-07-28

Similar Documents

Publication Publication Date Title
CA2439763C (en) Pharmaceutical compositions based on anticholinergics and pde-iv inhibitors
US20020193393A1 (en) Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
KR100940752B1 (ko) 티오트로퓸 염 및 살메테롤 염에 기초한 신규한 의약 조성물
US20040058950A1 (en) Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US6608054B2 (en) Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20040176338A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
IL174496A (en) Aerosol formulation for inhalation containing an anticholinergic agent
US20040192675A1 (en) Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
JP2004512359A (ja) 抗コリン作用薬及びコルチコステロイドをベースとする新規医薬組成物
HRP20040944A2 (en) Medicaments containing betamimetic drugs and a novel anticholinesterase drug
EA009936B1 (ru) Аэрозольная композиция для ингаляции, содержащая антихолинергическое средство
CA2629082A1 (en) Aerosol formulation for inhalation containing an anticholinergic agent
CA2629074A1 (en) Aerosol formulation for inhalation containing an anticholinergic agent
CA2628947A1 (en) Aerosol formulation for inhalation containing an anticholinergic agent
CA2575385A1 (en) Aerosol formulation for inhalation, containing an anticholinergenic agent
CA2629070A1 (en) Aerosol formulation for inhalation containing an anticholinergic agent
EA008386B1 (ru) Порошок для ингаляции, ингаляционный аэрозоль и раствор для ингаляции, содержащие стероиды и новое антихолинергическое средство
US20090221626A1 (en) Aerosol formulation for inhalation containing an anticholinergic agent
RU2361586C2 (ru) Комбинация из антихолинергического средства и стероида и ее применение для лечения заболеваний дыхательных путей путем ингаляции
CA2492026A1 (en) New pharmaceutical compositions based on new anticholinergics and pde-iv inhibitors
ZA200306221B (en) Novel medicament compositions on the basis of anti-cholinergics and PDE IV inhibitors.
JP2004512379A (ja) 新規医薬組成物
EA007048B1 (ru) Лекарственные средства, содержащие бетамиметики и новое антихолинергическое средство
JP2007523116A (ja) 抗コリン作用薬及びｐｅｇｓｕｎｅｒｃｅｐｔを基にした新規な医薬組成物
JP2007517820A (ja) スコピンエステル及びニコチンアミド誘導体を基にした新規な医薬組成物

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU